<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        18-90-02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SOLIAN 50MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMISULPRIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        62.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="sanofi-aventis" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AL06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solian® 50 mg, tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amisulpride ..................................……….…………………………………………………………………………50 mg
For one tablet
For the complete list of excipients, see Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
Flat, round tablet, with “AMI 50” engraved on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of schizophrenia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Usually:<br /> if the daily dose is &le; 400 mg, it is to be administered as a once-daily dose;<br /> If the daily dose exceeds 400 mg, it is to be administered as two divided doses.<br />Acute psychotic episodes<br />It is possible to start via the IM route for a few days, at a maximum dose of 400 mg/day, switching thereafter to oral<br />treatment.<br />Oral doses between 400 mg/day and 800 mg/day are recommended. The maximum dose should never exceed<br />1 200 mg. Given that there has been no large-scale safety assessment of doses higher than 1200 mg/day, these<br />doses should not be used.<br />The dosage should then be maintained or adjusted according to the patient&#39;s individual response.<br />In all cases, the maintenance treatment should be established individually with the minimum effective dose.<br />Predominantly negative episodes<br />Doses between 50 mg/day and 300 mg/day are recommended. Doses should be adjusted individually. The<br />optimum dosage is about 100 mg/day.<br />Children and adolescents<br />The efficacy and safety of amisulpride from the age of puberty up to 18 years has not been elucidated: available<br />data on the use of amisulpride in adolescents with schizophrenia are limited. As a result, amisulpride is not<br />recommended in patients from the age of puberty up to 18 years. Amisulpride is contraindicated for children under<br />15 years of age.<br />Elderly subjects<br />Amisulpride should be used with particular caution in this patient population due to the risk of hypotension and<br />sedation (see section 4.4).<br />Renal insufficiency<br />Amisulpride is eliminated via the renal route. In patients with renal insufficiency, the dose should be reduced by half<br />when creatinine clearance (CrCl) is between 30-60 ml/min and to a third in patients with CrCl between<br />10-30 ml/min.<br />As no data on patients with serious renal insufficiency (CrCl &lt;10 ml/min) are available, careful monitoring is<br />recommended in this population (see Section 4.4).</p><p>Hepatic insufficiency<br />Since amisulpride is weakly metabolized, a dosage reduction is not necessary in patients with hepatic insufficiency.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This medicine MUST NOT BE USED in the following cases:
 known hypersensitivity to amisulpride or to any of the ingredients of the medicinal product,
 serious hypertensive episodes have been reported in patients with pheochromocytoma using
antidopaminergic drugs, including some benzamides. It is therefore advisable to abstain from prescribing this
medicinal product in known or suspected pheochromocytoma carriers,
 children under 15 years of age, because no clinical data are available on this age group,
 breast-feeding,
 known or suspected prolactin-dependent tumors, e.g. prolactin-secreting pituitary adenoma and breast
cancer,
 in combination with levodopa (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Neuroleptic malignant syndrome<br />As with other neuroleptic agents, a neuroleptic malignant syndrome (hyperthermia, muscle rigidity, autonomic<br />disorders, impaired consciousness and elevated CPK levels) may occur. If patients suffer from hyperthermia,<br />particularly with high daily doses, all antipsychotic agents, including amisulpride, should be discontinued.<br />Prolongation of the QT interval<br />Amisulpride induces a dose-dependent prolongation of the QT interval. This effect, known to potentiate the risk of<br />serious ventricular arrhythmias, particularly of the torsades de pointes type, is enhanced in patients with bradycardia,<br />hypokalemia, or congenital or acquired prolonged QT interval (combination with a medicinal product which prolongs<br />the QTc interval) (see Section 4.8).<br />Consequently, when the clinical situation permits, it is recommended to ensure that there are no factors which could<br />promote the occurrence of this rhythm disorder before administration:<br /> bradycardia less than 55 bpm,<br /> hypokalemia,<br /> congenital prolongation of the QT interval,<br /> ongoing treatment with a medicinal product likely to cause marked bradycardia (&lt;55 bpm), hypokalemia,<br />delayed intracardiac conduction, or prolongation of the QTc interval (see Sections 4.3 and 4.5).<br />An ECG should be performed as part of the initial assessment of patients requiring long-term treatment with a<br />neuroleptic agent.<br />Stroke<br />In randomized, placebo-controlled clinical studies in elderly patients with dementia and treated with certain atypical<br />antipsychotic agents, a three-fold risk of stroke was observed versus placebo. The mechanism underlying this<br />increased risk is unknown. Increased risk with other antipsychotic agents or in other patient populations cannot be<br />ruled out. This medicinal product must be used with caution in patients with risk factors for stroke.<br />Elderly patients with dementia<br />The risk of mortality increases in elderly patients suffering from dementia-related psychosis and treated with<br />antipsychotic drugs.<br />Analysis of 17 placebo-controlled studies (mean duration of 10 weeks), conducted in patients mainly taking atypical<br />antipsychotic drugs, showed that the risk of mortality increased 1.6- to 1.7-fold in patients treated with these<br />medicinal products versus placebo.<br />After a mean treatment period of 10 weeks, the risk of mortality was 4.5% in the treated patient group versus 2.6% in<br />the placebo group.</p><p>Although the causes of death varied in the clinical trials with the atypical antipsychotic drugs, the majority of deaths<br />appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia).<br />Epidemiological studies suggest that treatment with conventional antipsychotic drugs may increase mortality, as is<br />the case for atypical antipsychotic drugs.<br />The respective contribution of the antipsychotic drug and patient characteristics to the increase in mortality found in<br />the epidemiological studies is unclear.<br />Venous thromboembolism<br />Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with<br />antipsychotic drugs often present acquired risk factors for VTE, any potential risk factors for VTE must be identified<br />before and during treatment with Solian and preventive measures should be taken if needed (see Section 4.8).<br />Hyperglycemia/metabolic syndrome<br />Cases of hyperglycemia or glucose intolerance and occurrence or exacerbation of diabetes have been reported in<br />patients treated with some antipsychotic drugs, including amisulpride (see Section 4.8).<br />Patients receiving Solian should undergo clinical and laboratory monitoring that complies with current<br />recommendations. Particular caution is recommended in patients with diabetes or with risk factors for diabetes.<br />Seizure<br />Amisulpride can lower the seizure threshold. Therefore patients with a history of seizures should be closely<br />monitored during treatment with Solian.<br />Special populations<br />As amisulpride is eliminated by the renal route, the dose should be decreased or an alternative treatment considered<br />in patients with renal insufficiency (see Section 4.2). There are no data concerning patients with serious renal<br />insufficiency (see Section 4.2)<br />Amisulpride, like all antipsychotics, should be used with particular caution in elderly patients due to the potential risk<br />of sedation and hypotension.<br />Amisulpride, like all antidopaminergic drugs, should be used with caution in patients with Parkinson&rsquo;s disease due<br />to the risk of worsening disease. Amisulpride should be used only if neuroleptic treatment is absolutely necessary.<br />Withdrawal syndrome<br />Withdrawal symptoms have been described following sudden discontinuation of high doses of antipsychotics.<br />Involuntary movements (e.g. akathisia, dystonia and dyskinesia) have been reported with amisulpride. It is therefore<br />advisable to discontinue amisulpride treatment gradually.<br />Other<br />It is inadvisable to use this medicinal product in combination with alcohol, antiparkinsonian dopamine agonists,<br />antiparasitic agents likely to induce torsades de pointes, methadone, other neuroleptic agents and medicinal<br />products likely to induce torsades de pointes (see Section 4.5).<br />Related to excipients<br />This medicinal product contains lactose. It is not recommended in patients with galactose intolerance, Lapp lactase<br />deficiency or glucose-galactose malabsorption syndrome (rare hereditary diseases).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>+ Sedative agents<br />It must be taken into account that many drugs or substances can have additive depressant effects on the central<br />nervous system and contribute to a decrease in alertness. These drugs include morphine derivatives (analgesics,<br />antitussives, and replacement treaments), neuroleptics, barbiturates, benzodiazepines, non-benzodiazepine<br />anxiolytics (such as meprobamate), hypnotics, sedative antidepressants (amitriptyline, doxepin, mianserine,<br />mirtazapine, trimipramine), sedative H1-antihistamines, centrally-acting antihypertensives, baclofen, and thalidomide.</p><p>+ Drugs likely to induce torsades de pointes<br />This serious cardiac rhythm disorder can be caused by a certain number of antiarrhythmic and non-antiarrhythmic<br />drugs. Hypokalemia (see Potassium-depleting agents) is a promoting factor, as is bradycardia (see Bradycardiainducing<br />agents) and pre-existing congenital or acquired QT interval prolongation.<br />This particularly concerns class IA and III antiarrhythmics as well as some neuroleptics.<br />For erythromycin, spiramycin, and vincamine, only forms administered intravenously are concerned by this<br />interaction.<br />In general, using two torsadogenic drugs concomitantly is contraindicated.<br />Nevertheless, methadone as well as certain sub-classes are exceptions to the rule:<br /> antiparasitics (halofantrine, lumefantrine, pentamidine) are only inadvisable in combination with other torsades<br />de pointes-inducing agents.<br /> neuroleptics likely to induce torsades de pointes are also inadvisable but not contraindicated in combination with<br />other torsadogenic drugs.<br />Contraindicated combinations<br />(See Section 4.3)<br />+ Levodopa<br />Mutual antagonism of effects between dopamine agonists and neuroleptics.<br />Inadvisable combinations<br />(See Section 4.4)<br />+ Antiparasitics likely to induce torsades de pointes (halofantrine, lumefantrine, pentamidine)<br />Increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />If possible, treatment with azole antifungals should be discontinued.<br />If the combination cannot be avoided, QT should be controlled before implementing treatment and ECG monitored.<br />+ Dopaminergic antiparkinsonian drugs (amantadine, apomorphine, bromocriptine, entacapone,<br />lisuride, pergolide, piribedil, pramipexole, ropinirole, selegiline)<br />Mutual antagonism of effects between dopamine agonists and neuroleptics.<br />Dopamine agonists can induce or worsen psychotic disorders. When it is necessary to use a neuroleptic in a patient<br />with Parkinson&rsquo;s disease who is taking dopamine agonists, the dopamine agonists must be gradually reduced and<br />finally discontinued (sudden withdrawal of dopamine agonists exposes the patient to a risk of neuroleptic malignant<br />syndrome).<br />+ Other drugs likely to induce torsades de pointes: class IA antiarrhythmics (quinidine, hydroquinidine,<br />disopyramide) and class III antiarrhythmics (amiodarone, sotalol, dofetilide, ibutilide), and other<br />drugs such as bepridil, cisapride, diphemanil, IV erythromycin, mizolastine, IV vincamine,<br />moxifloxacin, IV spiramycin.<br />Increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />+ Other neuroleptics likely to induce torsades de pointes (amisulpride,chlorpromazine, cyamemazine,<br />droperidol, haloperidol, levomepromazine, pimozide, pipotiazine, sertindole, sulpiride, sultopride,<br />tiapride, veralipride).<br />Increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />+ Alcohol consumption<br />Alcohol enhances the sedative effect of neuroleptics.<br />Impaired alertness may make it dangerous to drive or to use machines.<br />Consumption of alcoholic drinks or medicines containing alcohol should be avoided.<br />+ Methadone<br />Increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />Combinations requiring precautions for use</p><p>+ Beta-blockers in patients with heart failure (bisoprolol, carvedilol, metoprolol, nebivolol)<br />Increased risk of ventricular arrhythmias, particularly torsades de pointes. Clinical and ECG monitoring required.<br />+ Bradycardia-inducing agents (particularly class IA antiarrhythmics, beta-blockers, certain class III<br />antiarrhythmics, certain calcium channel blockers, digitalis drugs, pilocarpine, anticholinesterase<br />agents):<br />Increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />Clinical and ECG monitoring required.<br />+ Potassium-depleting agents (potassium-depleting diuretics, alone or in combination, stimulant<br />laxatives, glucocorticoids, tetracosactides and IV amphotericin B).<br />Increased risk of ventricular arrhythmias, particularly torsades de pointes.<br />Any hypokalemia should be corrected before administering amisulpride and clinical, electrolyte and ECG monitoring<br />carried out.<br />Combinations to be taken into consideration<br />+ Antihypertensives<br />Increased risk of hypotension, particularly postural hypotension.<br />+ Beta-blockers (except esmolol, sotalol and beta-blockers used for heart failure).<br />Vasodilator effect and risk of hypotension, particularly postural hypotension (additive effect).<br />+ Nitrate derivatives and related substances<br />Increased risk of hypotension, particularly postural hypotension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />In animal studies, amisulpride did not show reproductive toxicity. A decrease in fertility linked to the pharmacological<br />effects of the drug (prolactin mediated effect) was observed. No teratogenic effects of amisulpride were noted.<br />Very limited clinical data on exposed pregnancies are available therefore the safety of amisulpride during human<br />pregnancy has not been established. Use of the drug is not recommended during pregnancy unless the benefits<br />justify the potential risks.<br />If amisulpride is used during pregnancy, neonates may show adverse effects of amisulpride and thus appropriate<br />monitoring should be considered.<br />Lactation<br />Since no data are available about whether amisulpride is excreted in breast milk, breast-feeding is contra-indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients, especially those who drive and use machines, should be warned of the risk of drowsiness associated with<br />the use of this drug (see Section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects have been ranked by incidence using the following convention: very common (&ge; 1/10); common<br />(&ge; 1/100; &lt; 1/10); uncommon (&ge; 1/1,000; &lt; 1/100); rare (&ge; 1/10,000; &lt; 1/1,000); very rare (&lt; 1/10,000); unknown<br />frequency (cannot be estimated from the available data).<br />Data from clinical studies: the following adverse effects have been observed in controlled clinical studies. It can<br />sometimes be difficult to distinguish between adverse effects and symptoms of the underlying disease.</p><p>Nervous system disorders<br />Very common<br />Extrapyramidal symptoms (tremor, hypertonia, hypersalivation, akathisia, hypokinesia, dyskinesia) may occur. These<br />symptoms are generally moderate at optimal dosages and partially reversible without discontinuation of Solian but<br />with administration of anticholinergic antiparkinsonian medication.<br />The incidence of extrapyramidal symptoms, which are dose-dependent, is very low in patients being treated for<br />predominantly negative symptoms at doses of 50 mg/day to 300 mg/day.<br />Common<br />Acute dystonia (spasmodic torticollis, oculogyric crises, trismus, etc.) may appear. This is reversible without<br />discontinuation of amisulpride but with administration of an anticholinergic antiparkinsonian agent.<br />Drowsiness.<br />Uncommon<br />Tardive dyskinesia, characterized by involuntary movements of the tongue and/or face have been reported,<br />particularly after long-term administration.<br />Anticholinergic antiparkinsonian agents are ineffective or may induce worsening of the symptoms.<br />Seizures.<br />Psychiatric disorders<br />Common<br />Insomnia, anxiety, agitation, frigidity.<br />Gastrointestinal disorders<br />Common<br />Constipation, nausea, vomiting, dry mouth.<br />Endocrine disorders<br />Common<br />Increase in plasma prolactin levels which is reversible on treatment discontinuation. This may result in the following<br />clinical signs and symptoms: galactorrhea, amenorrhea, gynecomastia, breast tenderness, erectile dysfunction.<br />Metabolism and nutrition disorders<br />Uncommon<br />Hyperglycemia (see Section 4.4).<br />Cardiac disorders<br />Common<br />Hypotension.<br />Uncommon<br />Bradycardia.<br />Investigations<br />Common<br />Weight gain.<br />Uncommon<br />Elevated liver enzymes, mainly transaminases.<br />Immune system disorders<br />Uncommon<br />Allergic reactions.</p><p>POST-MARKETING EXPERIENCE<br />The following undesirable effects have been spontaneously reported:<br />Nervous system disorders<br />Unknown frequency<br />Neuroleptic malignant syndrome (see Section 4.4).<br />Cardiac disorders<br />Unknown frequency<br />Prolongation of the QT interval. Ventricular arrhythmias such as torsades de pointes or ventricular tachycardia that<br />can lead to ventricular fibrillation or cardiac arrest, sudden death (see Section 4.4).<br />Vascular disorders:<br />Unknown frequency<br />Cases of venous thromboembolism, including cases of pulmonary embolism, that were sometimes fatal, and deep<br />vein thrombosis, have been reported with antipsychotic drugs (see Section 4.4).<br />Skin and subcutaneous tissue disorders:<br />Unknown frequency<br />Angioedema, urticaria.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To date, data concerning acute overdose with amisulpride are limited. The reported signs and symptoms generally<br />result from increased pharmacological activity manifested clinically by drowsiness, sedation, coma, hypotension<br />and extrapyramidal symptoms. Cases with a fatal outcome have been reported mainly in combination with other<br />antipsychotic drugs.<br />There is no known specific antidote to amisulpride. In the event of acute overdose, use of concomitant medication<br />must be investigated and appropriate measures taken:<br /> Close monitoring of vital functions.<br /> Cardiac monitoring (risk of prolongation of the QT interval) until the patient recovers.<br /> If severe extrapyramidal symptoms occur, anticholinergic agents must be administered.<br /> Since amisulpride is poorly dialyzable, hemodialysis is of limited use to eliminate the drug.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ANTIPSYCHOTIC, ATC code: N05AL05<br />Amisulpride is an antipsychotic drug belonging to the class of substituted benzamides.<br />Its pharmacodynamic profile is characterized by a selective and predominant affinity for the dopaminergic D2 and<br />D3receptors of the limbic system. Amisulpride is devoid of affinity for serotonin receptors or other neuroreceptors<br />suchas histamine, cholinergic and adrenergic receptors.<br />In animal studies, at high doses, amisulpride preferentially blocks the dopaminergic neurones of the mesolimbic<br />system compared to those in the striatal system. This specific affinity could explain the predominant antipsychotic<br />effects of amisulpride compared with its extrapyramidal effects.<br />At low doses, amisulpride preferentially blocks the presynaptic D2 / D3 dopaminergic receptors, which could explain<br />its effects on negative symptoms.<br />In a controlled, double-blind study versus haloperidol conducted in 191 patients with acute schizophrenia,<br />improvement of secondary negative symptoms was significantly greater with amisulpride in comparison with<br />haloperidol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In man, amisulpride shows two absorption peaks: the first is attained rapidly, one hour post-dose and the second<br />between 3 and 4 hours after administration.<br />Corresponding plasma concentrations are 39 &plusmn; 3 and 54 &plusmn; 4 ng/ml after administration of a 50 mg dose,<br />respectively.<br />The volume of distribution is 5.8 l/kg; plasma protein binding is low (16%) and no drug interactions related to</p><p>plasma protein binding are suspected. Absolute bioavailability is 48%.<br />Amisulpride is poorly metabolized: two inactive metabolites have been identified and account for approximately 4%<br />of the total amount of drug eliminated.<br />There is no accumulation of amisulpride and its pharmacokinetics remain unchanged after the administration of<br />repeated doses.<br />The elimination half-life is approximately 12 hours after an oral dose.<br />Amisulpride is eliminated unchanged in the urine. 50% of an intravenous dose is excreted via the urine, of which<br />90% is eliminated in the first 24 hours.<br />Renal clearance is approximately 330 ml/min.<br />A carbohydrate-rich meal significantly decreases the AUC, Tmax and Cmax of amisulpride but no changes are<br />seen after a high-fat meal. The effect of these findings during treatment with amisulpride is not known.<br />Hepatic insufficiency<br />Since amisulpride is poorly metabolized, dosage reduction is not necessary in patients with hepatic insufficiency.<br />Renal insufficiency<br />The elimination half-life is unchanged in patients with renal insufficiency while total clearance is reduced by a factor<br />of 2.5 to 3.<br />The AUC of amisulpride in mild kidney failure is increased two-fold and almost ten-fold in moderate kidney failure.<br />Experience is limited, however, and there are no available data on doses higher than 50 mg.<br />Amisulpride is poorly dialyzable.<br />Elderly subjects<br />The pharmacokinetic data available for subjects aged over 65 years show that a 10-30% increase occurs in Cmax,<br />T1/2 and AUC after a single dose of 50 mg.<br />No data are available after repeat dosing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxicological profile of amisulpride is dominated by the pharmacological effects of the compound. Toxicity<br />studies after repeated administrations showed no target organ impairment. The compound is devoid of teratogenic<br />or genotoxic effects. Carcinogenesis studies have demonstrated hormone-dependent tumors in rodents. These are<br />not of any clinical relevance in man.<br />Decreased fertility related to the pharmacological properties of the product (prolactin-mediated effects) was<br />observed<br />in animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type A sodium starch glycolate, lactose monohydrate, microcrystalline cellulose, hypromellose, magnesium<br />stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special precautions for storage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30, 60 or 150 tablets in heat-formed blister packs (PVC/aluminium).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                sanofi-aventis France
1-13, boulevard Romain Rolland
75014 Paris
France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mar 2011
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>